Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 3
2016 1
2017 2
2018 1
2019 1
2020 4
2021 1
2022 8
2023 3

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial.
Bistervels IM, Buchmüller A, Wiegers HMG, Ní Áinle F, Tardy B, Donnelly J, Verhamme P, Jacobsen AF, Hansen AT, Rodger MA, DeSancho MT, Shmakov RG, van Es N, Prins MH, Chauleur C, Middeldorp S; Highlow Block writing committee; Highlow Investigators. Bistervels IM, et al. Lancet. 2022 Nov 19;400(10365):1777-1787. doi: 10.1016/S0140-6736(22)02128-6. Epub 2022 Oct 28. Lancet. 2022. PMID: 36354038 Clinical Trial.
Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study.
Charlier C, Perrodeau É, Leclercq A, Cazenave B, Pilmis B, Henry B, Lopes A, Maury MM, Moura A, Goffinet F, Dieye HB, Thouvenot P, Ungeheuer MN, Tourdjman M, Goulet V, de Valk H, Lortholary O, Ravaud P, Lecuit M; MONALISA study group. Charlier C, et al. Lancet Infect Dis. 2017 May;17(5):510-519. doi: 10.1016/S1473-3099(16)30521-7. Epub 2017 Jan 28. Lancet Infect Dis. 2017. PMID: 28139432 Free article.
A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML.
Mekinian A, Zhao LP, Chevret S, Desseaux K, Pascal L, Comont T, Maria A, Peterlin P, Terriou L, D'Aveni Piney M, Gourin MP, Vey N, Rauzy OB, Grobost V, Bezanahary H, Dimicoli-Salazar S, Banos A, Wickenhauser S, De Renzis B, Durot E, Natarajan-Amé S, Voillat L, Chermat F, Lemaire K, Jachiet V, Himberlin C, Thépot S, Diaz JMT, Frenzel L, Gyan E, Denis G, Hirsch P, Kosmider O, Ades L, Fain O, Fenaux P. Mekinian A, et al. Among authors: grobost v. Leukemia. 2022 Nov;36(11):2739-2742. doi: 10.1038/s41375-022-01698-8. Epub 2022 Sep 14. Leukemia. 2022. PMID: 36104395 Clinical Trial. No abstract available.
Givosiran in acute intermittent porphyria: A personalized medicine approach.
Poli A, Schmitt C, Moulouel B, Mirmiran A, Talbi N, Rivière S, Cerutti D, Bouchoule I, Faivre A, Grobost V, Douillard C, Duchêne F, Fiorentino V, Dupré T, Manceau H, Peoc'h K, Puy H, Lefebvre T, Gouya L. Poli A, et al. Among authors: grobost v. Mol Genet Metab. 2022 Mar;135(3):206-214. doi: 10.1016/j.ymgme.2022.01.002. Epub 2022 Jan 10. Mol Genet Metab. 2022. PMID: 35058124
Ischaemic skin lesions with multi-organ failure due to cocaine intake.
Devers É, Courouge-Dorcier D, Arpajou G, Chevenet C, Chevaleyre A, Grobost V, D'incan M. Devers É, et al. Among authors: grobost v. Eur J Dermatol. 2020 Mar 27. doi: 10.1684/ejd.2020.3703. Online ahead of print. Eur J Dermatol. 2020. PMID: 32229431 No abstract available.
Comparison between idiopathic and VEXAS-relapsing polychondritis: analysis of a French case series of 95 patients.
Khitri MY, Guedon AF, Georgin-Lavialle S, Terrier B, Saadoun D, Seguier J, le Besnerais M, De Moreuil C, Denis G, Gerfaud-Valentin M, Allain JS, Maria A, Bouillet L, Grobost V, Galland J, Kosmider O, Dumont A, Devaux M, Subran B, Schmidt J, Marianetti-Guingel P, Audia S, Palat S, Roux-Sauvat M, Jachiet V, Hirsch P, Fain O, Mekinian A; French VEXAS group and MINHEMON. Khitri MY, et al. Among authors: grobost v. RMD Open. 2022 Jul;8(2):e002255. doi: 10.1136/rmdopen-2022-002255. RMD Open. 2022. PMID: 35868738 Free PMC article.
Development and validation of a quality of life measurement scale specific to hereditary hemorrhagic telangiectasia: the QoL-HHT.
Le TTT, Martinent G, Dupuis-Girod S, Parrot A, Contis A, Riviere S, Chinet T, Grobost V, Espitia O, Dussardier-Gilbert B, Alric L, Armengol G, Maillard H, Leguy-Seguin V, Leroy S, Rondeau-Lutz M, Lavigne C, Mohamed S, Chaussavoine L, Magro P, Seguier J, Kerjouan M, Fourdrinoy S. Le TTT, et al. Among authors: grobost v. Orphanet J Rare Dis. 2022 Jul 19;17(1):281. doi: 10.1186/s13023-022-02426-2. Orphanet J Rare Dis. 2022. PMID: 35854330 Free PMC article.
Antiplatelet and anticoagulant therapies in hereditary hemorrhagic telangiectasia: A large French cohort study (RETROPLACOTEL).
Grobost V, Hammi S, Pereira B, Guilhem A, Duffau P, Seguier J, Parrot A, Gautier G, Alric L, Kerjouan M, Le Guillou X, Simon D, Chaussavoine L, Rondeau-Lutz M, Leguy-Seguin V, Delagrange L, Lavigne C, Maillard H, Dupuis-Girod S; French HHT group. Grobost V, et al. Thromb Res. 2023 Sep;229:107-113. doi: 10.1016/j.thromres.2023.07.001. Epub 2023 Jul 6. Thromb Res. 2023. PMID: 37437516
23 results